Changes to Anaphore's senior management
This article was originally published in Scrip
Anaphore has appointed Dr Michael Haller senior vice-president of strategic partnerships and H Casey Logan senior vice-president of business development. Dr Haller will manage the company's R&D partnership with Mitsubishi Tanabe Pharma Corporation, and most recently served as vice-president of alliance management and portfolio development at Halozyme Therapeutics. Mr Logan previously led corporate development and strategic planning efforts at Anadys Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.